June 2026 Quarterly Activities Report and Appendix 4C
Filed with ASX · · 8 pages · English
Story so far
Earlier from TrivarX
- Stabl-Im clinical trial supply milestone achieved
- CRO Engaged to Advance Stabl-Im Phase 1 Trial
- March 2026 Quarterly Activities Report and Appendix 4C
- Dr Danielle Meyrick appointed as CEO
- Appendix 4D & Half-Year Financial Report to 31 December 2025
Later from TrivarX
- Stabl-Im Clinical Development Update
- Syntro Health Appointed to Support Stabl-Im Clinical Program
- September 2026 Quarterly Activities Report and Appendix 4C
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX